<qa>  What is the name of the WHICH LYMPHOCYTIC LEUKEMIABCL-2 INHIBITOR GDC-0199 IN COMBINATION WITH OBINUTUZUMAB AND IBRUTINIB IN TREATING PATIENTS WITH RELAPSED, REFRACTORY, OR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA: 